单位：[1]Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital South Campus, Shanghai, P.R. China.[2]Department of Urology, Beijing Friendship Hospital, Capital Medical University of Tongzhou District, Beijing, P.R. China.临床科室泌尿外科泌尿外科首都医科大学附属北京友谊医院
Background: Zhang et al. characterized a novel oncogenic long noncoding RNA (lncRNA) named NR2F2-AS1 in lung cancer. In this study, the role of lncRNA NR2F2-AS1 in clear cell renal cell carcinoma (ccRCC) was explored. Materials and Methods: Levels of NR2F2-AS1 and Rac1 mRNA expression in both cancer and noncancer tissues from 60 patients with ccRCC were measured by performing RT-qPCR. NR2F2-AS1 siRNA silencing and overexpression experiments were performed to analyze the role of NR2F2-AS1 in regulating Rac1 expression. Cell stemness was analyzed by stemness assay. Results: NR2F2-AS1 was upregulated in ccRCC, and high NR2F2-AS1 expression levels in ccRCC tissues were associated with poor survival. Rac1 was also upregulated in ccRCC and positively correlated with NR2F2-AS1. In ccRCC cells, NR2F2-AS1 overexpression mediated the upregulation of Rac1, whereas NR2F2-AS1 siRNA was accompanied by Rac1 downregulation. NR2F2-AS1 and Rac1 overexpression resulted in the increased ccRCC cell stemness, whereas NR2F2-AS1 and Rac1 siRNA silencing played an opposite role. Rac1 overexpression inhibited the role of NR2F2-AS1 siRNA silencing. Conclusions: NR2F2-AS1 may upregulate Rac1 to increase cancer stemness in ccRCC.
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区肿瘤学4 区药学4 区核医学
最新[2025]版：
大类|4 区医学
小类|4 区医学：研究与实验4 区肿瘤学4 区药学4 区核医学
JCR分区：
出版当年[2018]版：
Q3MEDICINE, RESEARCH & EXPERIMENTALQ3RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGINGQ3PHARMACOLOGY & PHARMACYQ4ONCOLOGY
最新[2023]版：
Q2RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGINGQ3MEDICINE, RESEARCH & EXPERIMENTALQ3ONCOLOGYQ3PHARMACOLOGY & PHARMACY
第一作者单位：[1]Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital South Campus, Shanghai, P.R. China.
通讯作者：
通讯机构：[2]Department of Urology, Beijing Friendship Hospital, Capital Medical University of Tongzhou District, Beijing, P.R. China.[*1]Department of Urology, Beijing Friendship Hospital, Capital Medical University of Tongzhou District, No. 101 Luyuan East Road, Tongzhou District, Beijing 100050, P.R. China
推荐引用方式(GB/T 7714)：
Chen Lin,Zhang Dongxing,Ding Tao,et al.LncRNA NR2F2-AS1 Upregulates Rac1 to Increase Cancer Stemness in Clear Cell Renal Cell Carcinoma[J].CANCER BIOTHERAPY and RADIOPHARMACEUTICALS.2020,35(4):301-306.doi:10.1089/cbr.2019.3319.
APA：
Chen, Lin,Zhang, Dongxing,Ding, Tao,Liu, Feng,Xu, Xiaolin...&Shen, Hongliang.(2020).LncRNA NR2F2-AS1 Upregulates Rac1 to Increase Cancer Stemness in Clear Cell Renal Cell Carcinoma.CANCER BIOTHERAPY and RADIOPHARMACEUTICALS,35,(4)
MLA：
Chen, Lin,et al."LncRNA NR2F2-AS1 Upregulates Rac1 to Increase Cancer Stemness in Clear Cell Renal Cell Carcinoma".CANCER BIOTHERAPY and RADIOPHARMACEUTICALS 35..4(2020):301-306
